Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT and BMS986365 in High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy
NCT07335796Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2030
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986365 in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: active, not recruiting.
02
Drugs
BMS-986365
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07335796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335796.